Phase IIb randomized trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback